NRX Pharmaceuticals (NRXP) Share-based Compensation (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Share-based Compensation of $600000.0 for Q1 2026, up 242.86% quarter-over-quarter from -$420000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Share-based Compensation (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Share-based Compensation for 7 consecutive years, with $600000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation changed N/A year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $600000.0 (up 153.16% YoY), while the FY2025 annual figure was $500000.0, up 2.88% from the prior year.
- Share-based Compensation advanced to $600000.0 in Q1 2026 per NRXP's latest filing, from -$420000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.6 million in Q4 2022 and bottomed at -$1.6 million in Q4 2023.
- Historically, Share-based Compensation has averaged $454187.5 across 5 years, with a median of $296500.0 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 258.6% — and 2025, when it slumped 1076.74%.
- NRX Pharmaceuticals' Share-based Compensation stood at $3.6 million in 2022, then slumped by 144.03% to -$1.6 million in 2023, then surged by 102.7% to $43000.0 in 2024, then plunged by 1076.74% to -$420000.0 in 2025, then jumped by 242.86% to $600000.0 in 2026.
- Business Quant data shows NRXP's Share-based Compensation at $600000.0 in Q1 2026, -$420000.0 in Q4 2025, and $68000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 139,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 600,000.00 |
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | -420,000.00 |
| Dec 31, 2025 | -420,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Jun 30, 2025 | 67,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Dec 31, 2023 | -1.59 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | 351,000.00 |
| Sep 30, 2023 | 351,000.00 |